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Abstract
Background: The allocation of limited available healthcare resources demands an agreed rational allocation
principle and the consequent priority setting. We assessed the association between economic evaluations of
healthcare interventions published in Spain (1983-2008) and the disease burden in the population.
Methods: Electronic databases (e.g., PubMed/MEDLINE, SCOPUS, ISI Web of Knowledge, CRD, IME, IBECS) and
reports from health technology assessment agencies were systematically reviewed. For each article, multiple
variables were recorded such as: year and journal of publication, type of study, health intervention targetted,
perspective of analysis, type of costs and sources of information, first author’s affiliation, explicit recommendations
aimed at decision-making, and the main disease cause to which the intervention was addressed. The following
disease burden measures were calculated: years of life lost (YLLs), years lived with disability (YLDs), disability-
adjusted life years (DALYs), and mortality by cause. Correlation and linear regression models were fitted.
Results: Four hundred and seventy-seven economic evaluations were identified. Cardiovascular diseases (15.7%),
infectious diseases (15.3%), malignant neoplasms (13.2%), and neuropsychiatric diseases (9.6%) were the conditions
most commonly addressed. Accidents and injuries, congenital anomalies, oral conditions, nutritional deficiencies
and other neoplasms were the categories with a lowest number of studies (0.6% for each of them). For the main
disease categories (n = 20), a correlation was seen with: mortality 0.67 (p = 0.001), DALYs 0.63 (p = 0.003), YLLs
0.54 (p = 0.014), and YLDs 0.51 (p = 0.018). By disease sub-categories (n = 51), the correlations were generally low
and non statistically significant.
Conclusions: Examining discrepancies between economic evaluations in particular diseases and the overall burden
of disease helps shed light on whether there are potentially over- and under-investigated areas. The approach
taken could help policy-makers understand whether resources for economic evaluation are being allocated by
using summary measures of population health.
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Background
Economic evaluation using clinical, epidemiological and
economic data allows for a comparative analysis of alter-
native actions in terms of costs and health outcomes.
Nowadays, the explicit use of the information from
these studies is presumed to be a valuable tool for deci-
sion-making. Its consideration is justified by the limited
amount of resources and is ethically grounded because
those resources used inefficiently involve a lost opportu-
nity to address other population health needs.
In recent decades the number of economic evaluations
has increased over time [1] for several reasons, includ-
ing: raised healthcare costs, population aging, epidemio-
logical transition to chronic diseases, as well as
continuous development of technological innovation
and the explicit need to ensure rational use of existing
healthcare resources. Ideally, research priorities should
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efficient investments in interventions with proven bene-
fits in health outcomes. The efficiency level could be
measured by economic evaluation studies, while the
population health needs may be evaluated through
health losses attributable to fatal and non-fatal outcomes
of the diseases, injuries and associated risk factors, also
called burden of disease [3,4].
A substantial number of economic evaluations would
be thus expected, aimed at measuring the efficiency of
interventions for diseases with a high epidemiologic and
socioeconomic burden. Some analyses have investigated
the allocation of resources for health research in the
past [5-9]. In the same line, Neumann et al.[ 1 0 ]a n a -
lyzed the relationship between the disease burden and
economic evaluations performed in the U.S. and other
Western countries. The study by Neumann et al.w a s
the first to explore research priorities for a specific type
of economic evaluation in healthcare: cost-utility ana-
lyses. However, none of the systematic reviews of the
use of economic evaluation published have approached
this issue in Southern European countries such as Spain
[1,2,11,12].
In this context, we examined whether full-economic
evaluations of healthcare interventions (e.g., evaluations
where both costs and outcomes have been measured)
are aimed at those conditions generating a higher bur-
den of disease. We expect that the information obtained
would contribute to the current debate on establishing
health priorities of future health technology assessment
(HTA) research agendas.
Methods
This is an observational study that summarizes the
main characteristics of economic evaluation studies
published in Spain (1983-2008), updates the calculation
of the Burden of Disease study in the Spanish popula-
tion, and investigates the association between economic
evaluation research and the burden of disease in the
population.
Systematic review of economic evaluation studies
The results from a previous review that examined eco-
nomic evaluation studies published within the years
1983-1999 [1], updated with the studies published until
2008 [2] were analyzed. Briefly, a systematic review was
performed in PubMed/MEDLINE, SCOPUS, ISI Web of
Knowledge, Databases of the Centre for Reviews and
Dissemination (CRD), as well as Índice Médico Español
(IME) and Índice Bibliográfico Español en Ciencias de la
Salud (IBECS). Medical subject headings (MeSH)
descriptors were used distributed into two blocks: eco-
nomic evaluation and geographical area. For the section
of geographical area, the search was based on a
previously validated approach [13] to minimise bias
regarding the indexing of geographical items. The full
list of terms used is shown in the additional file 1:
“Search terms used in the bibliographic review”.
Furthermore, manual searches were made for reports
from HTA agencies and publications in specialized
Spanish journals partially included in the abovemen-
tioned databases.
Selection criteria
We included full-economic evaluations (e.g., cost mini-
mization analysis [CMA], cost-effectiveness analysis
[CEA], cost-utility analysis [CUA] or cost-benefit analy-
sis [CBA]) that evaluated interventions performed in
Spain aimed at specific disease conditions. Review stu-
dies, editorials, and abstracts of congresses were
excluded. If an article was found repeated in several
publications, that published earlier and/or in a journal
with higher impact factor was included.
Classification parameters
For each study selected, we obtained the following
information: year and journal of publication, type of
study, health intervention targetted, perspective of ana-
lysis (in terms of which costs are considered e.g.,
society, healthcare system, hospital, others), type of
costs (e.g., direct or indirect) and sources of informa-
tion, affiliation of the first author, explicit recommenda-
tions aimed at decision-making, and the main cause of
disease to which the intervention or health program
was addressed. The main disease cause was defined
according to the Global Burden of Disease (GBD) study
classification [3,4]. The source of funding was also
included. In this case, the studies reviewed were consid-
ered to be private when they mentioned funding by any
profit-making private setting or if any of the authors
was working in a private company. The non-systematic
use of the economic evaluation terms by some papers
led to assigning the type of study after carefully reading
the article, paying special attention to the costs, effec-
tiveness measures used and presentation of the research
results (e.g., cost per life year gained or cost per qual-
ity-adjusted life year). The studies were reviewed inde-
pendently by two investigators, downloading the
information in a predesigned database. Any disagree-
ments were resolved by discussion.
Updating the calculation of the burden of disease
The Burden of Disease study in the Spanish population
is based on previous analyses. Methods are described in
further detail elsewhere [9,14]. We estimated the burden
of disease using disability-adjusted life years (DALYs), a
time-based summary measure of population health com-
bining the years of life lost (YLLs) for early death and
the years of life lost due to the time living with disability
(YLDs) [3,15]. Mortality data for disease specific causes
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tion used were: the population corresponding to the
estimation of the National Institute of Statistics [16],
deaths by gender, age and cause for 2006 from the
national mortality records [17] and estimations for the
WHO Euro-A sub-region of the GBD study recently
published [4].
Statistical analysis
A descriptive analysis was performed using frequency
and percentage counts. The possible association between
economic evaluations and burden of disease measures
was analyzed using parametric (Pearson’s r) and non-
parametric correlation analyses (Spearman’s r). The Kol-
mogorov-Smirnov and Shapiro-Wilk tests were applied
to assess the normality of the data. Dependence among
variables was investigated with linear regression models.
In this case, the economic evaluations were the depen-
dent variable and the disease burden measures the inde-
pendent variable. As the different measures did not
f o l l o wan o r m a ld i s t r i b u t i o n ,t h ed a t aw e r el o g -
transformed.
Results
Main characteristics of the economic evaluations studies
Sixteen out of 87 identified studies from the 1983-
1999 review [1] were excluded for not meeting the
defined criteria. Four hundred and six articles met the
selection criteria for the period 2000-2008, and were
added to the 71 studies previously identified, obtain-
ing a total sample of 477 studies (see additional file 2:
“Flow diagram of systematic review to identify eligible
studies”) [2]. Table 1 details the characteristics of the
studies reviewed. The CEA prevailed as the most
common technique (62.5% of the total) and the health
system perspective was the most commonly used
(42.1%). In 70.0% of the studies, the main intervention
evaluated was treatments, and 17.4% approached pre-
ventive interventions (94.0% of them with medical
judgement, e.g., vaccines). Furthermore, a large part
of the studies did not specify the funding source; in
those stating it (267 studies), the profit-making
(76.8%) prevailed over the non-profit making nature
(23.2%).
Cardiovascular diseases (15.7%), infectious and parasitic
diseases (15.3%), and malignant neoplasms (13.2%) were
the disease categories (n = 20) most commonly studied.
Accidents and injuries, congenital anomalies, oral condi-
tions, nutritional deficiencies and other neoplasms were
the categories with a lowest number of studies (0.6%
from the total for each of them) (Table 2). The disease
sub-categories (n = 51) most prevalent in the studies
were lower respiratory infections (5.7%), ischemic heart
disease (5.7%), hepatitis B and C (3.3%) and HIV-AIDS
(3.1%) (Table 3).
Table 1 Main characteristics of the economic evaluation
studies
Characteristics n (%)
Study type
Cost-effectiveness analysis (CEA) 298
(62.5)
Cost-minimization analysis (CMA) 78 (16.4)
Cost-utility analysis (CUA) 73 (15.3)
Cost-benefit analysis (CBA) 28 (5.9)
Health research activities
Prevention of disease and conditions, and promotion of
well-being
83 (17.4)
Medically oriented (e.g. chemoprevention, vaccines) 78 (16.4)
Education/behaviour 5 (1.0)
Detection, screening and diagnosis 53 (11.1)
Screening 48 (10.1)
Resources and procedures 5 (1.0)
Treatments and therapeutic interventions 334
(70.0)
Medically oriented (e.g. pharmaceuticals) 263
(55.1)
Devices and procedures 33 (6.9)
Surgery 28 (5.9)
Education/behaviour 10 (2.1)
Rehabilitation 7 (1.5)
Methods
Decision analysis 162
(34.0)
Observational studies 111
(23.3)
Not explicit 88 (18.4)
Markov or other simulation models 74 (15.5)
Clinical trials 42 (8.8)
Perspective adopted
Healthcare system 201
(42.1)
Non explicit 121
(25.4)
Hospital 93 (19.5)
Society 59 (12.4)
Others 3 (0.6)
Costs
Direct 404
(84.7)
Direct and indirect 73 (15.3)
Cost information
Explicit 359
(75.3)
Non explicit 118
(24.7)
Funding source
Non explicit 210
(44.0)
For profit 205
(43.0)
Non for profit 62 (13.0)
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Neuropsychiatric conditions were the main cause of
DALYs accounting for 29.2%. Malignant neoplasms
ranked second followed by cardiovascular diseases,
generating 15.9% and 12.9%, respectively (Table 2).
The subcategories selected (Table 3) included most
remarkably the weight of DALYs in unipolar depres-
sion (8.3%), Alzheimer and other dementias (6.7%),
ischemic heart disease (4.6%), age-related hearing loss
(3.9%), cerebrovascular diseases (3.7%) and lung cancer
(3.4%). Tables 2 and 3 show how the assessment of the
impact of the various diseases in population health can
change upon considering the effect of mortality alone
or adding disability or poor health.
Association between economic evaluation research and
disease burden
The interventions evaluated were aimed mainly at the
study of non-communicable diseases (74.2% of the total)
and this group in turn generates the highest mortality
(90.0% deaths) and burden of disease (88.6% DALYs).
There is a mismatch between DALYs and the number
of economic evaluations. For example, communicable,
maternal, perinatal and nutritional conditions accounted
for 4.9% of DALYs and 25.2% of the economic analyses,
while 0.6% of the studies were aimed at the study of
accidents and injuries despite accounting for 6.5% of
DALYs (see Figure 1). Neuropsychiatric conditions
accounted for 29.2% of DALYs vs 9.6% of the economic
Table 1 Main characteristics of the economic evaluation
studies (Continued)
Affiliation of the first author
Hospital 243
(50.9)
Private (e.g. consulting, pharmaceutical industry) 99 (20.7)
University 56 (11.7)
Administration 55 (11.5)
Primary care 17 (3.6)
Non explicit 7 (1.5)
Recommendations
Yes 392
(82.2)
No 85 (17.8)
Table 2 Summary of burden of disease measures and economic evaluations for 20 disease-specific categories
National Burden of Disease in Spain 2006 Economic
evaluations
Disease categories* DALYs in thousands
(%)
YLLs in thousands
(%)
YLDs in thousands
(%)
Mortality in thousands
(%)
Studies n (%)
Neuropsychiatric conditions 1,467.9 (29.2) 110.9 (5.2) 1.356.9 (46.8) 28.7 (7.7) 46 (9.6)
Malignant neoplasms 798.7 (15.9) 720.2 (33.9) 78.5 (2.7) 101.0 (27.2) 63 (13.2)
Cardiovascular diseases 651.0 (12.9) 517.9 (24.4) 133.1 (4.6) 124.8 (33.6) 75 (15.7)
Sense organ diseases 409.2 (8.1) 0.0 (0.0) 409.2 (14.1) 0.0 (0.0) 12 (2.5)
Respiratory diseases 343.8 (6.8) 123.7 (5.8) 220.1 (7.6) 31.7 (8.5) 22 (4.6)
Accidents and injuries 326.3 (6.5) 241.6 (11.4) 84.7 (2.9) 16.1 (4.3) 3 (0.6)
Musculoskeletal diseases 234.3 (4.6) 11.4 (0.5) 222.9 (7.7) 3.5 (0.9) 31 (6.5)
Digestive diseases 213.6 (4.3) 120.8 (5.7) 92.8 (3.2) 20.0 (5.4) 30 (6.3)
Infectious and parasitic
diseases
113.9 (2.3) 66.9 (3.1) 47.0 (1.6) 7.4 (2.0) 73 (15.3)
Diabetes mellitus 98.7 (2.0) 39.2 (1.8) 59.4 (2.0) 10.0 (2.7) 26 (5.4)
Endocrine and blood
disorders
60.2 (1.2) 19.4 (0.9) 40.8 (1.4) 2.8 (0.7) 19 (4.0)
Genitourinary diseases 52.6 (1.0) 33.0 (1.5) 19.6 (0.7) 9.7 (2.6) 14 (2.9)
Congenital anomalies 51.0 (1.0) 27.2 (1.3) 23.8 (0.8) 1.0 (0.3) 3 (0.6)
Perinatal conditions 49.0 (1.0) 33.1 (1.6) 15.9 (0.5) 1.0 (0.3) 4 (0.8)
Respiratory infections 36.7 (0.7) 31.6 (1.5) 5.1 (0.2) 8.8 (2.4) 28 (5.9)
Oral conditions 34.4 (0.7) 0.1 (0.0) 34.3 (1.2) 0.0 (0.0) 3 (0.6)
Nutritional deficiencies 27.7 (0.5) 1.1 (0.0) 26.6 (0.9) 0.3 (0.1) 3 (0.6)
Other neoplasms 21.4 (0.4) 21.4 (1.0) 0.0 (0.0) 3.5 (0.9) 3 (0.6)
Maternal conditions 19.1 (0.4) 0.4 (0.0) 18.7 (0.6) 0.0 (0.0) 12 (2.5)
Skin diseases 11.0 (0.2) 3.4 (0.2) 7.6 (0.3) 1.1 (0.3) 7 (1.5)
Total 5,020.8 (100) 2,123.6 (100) 2,897.2 (100) 371.5 (100) 477 (100)
*Disease categories are presented in decreasing order of DALYs estimates in Spain (2006).
DALYs: Disability adjusted life years; YLLs: Years of life lost; YLDs: Years lived with disability.
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Disease
subcategories
DALYs %
of total
Studies* % of
total (rank)
Disease
subcategories
YLLs %
of total
Studies* % of
total (rank)
Disease
subcategories
YLDs %
of total
Studies* % of
total (rank)
Disease
subcategories
Mortality
% of total
Studies* % of
total (rank)
Unipolar
depression
8.3 1.9 (10) Ischemic heart
disease
9.2 5.7 (2) Unipolar
depression
14.3 1.9 (10) Ischemic heart
disease
10.3 5.7 (2)
Alzheimer’s and
other dementias
6.7 0.4 (28) Lung cancer 7.8 2.5 (7) Alzheimer’s and
other dementias
9.6 0.4 (28) Cerebrovascular
disease
9.2 1.3 (14)
Ischemic heart
disease
4.6 5.7 (2) Cerebrovascular
disease
6.1 1.3 (14) Hearing loss, adult
onset
6.8 0.2 (40) Alzheimer’s and
other dementias
5.9 0.4 (28)
Hearing loss, adult
onset
3.9 0.2 (40) Colorectal cancer 4.0 1.3 (15) Macular
degeneration
4.4 0.6 (24) Lung cancer 5.7 2.5 (7)
Cerebrovascular
disease
3.7 1.3 (14) Breast cancer 2.7 2.5 (8) Osteoarthritis 4.3 1.9 (11) COPD 4.5 2.7 (5)
Lung cancer 3.4 2.5 (7) COPD 2.7 2.7 (5) Migraine 2.7 0.8 (19) Colorectal cancer 3.8 1.3 (15)
Macular
degeneration
2.6 0.6 (24) Alzheimer’s and
other dementias
2.6 0.4 (28) Drug use
disorders
2.3 0.2 (41) Lower respiratory
infections
2.4 5.7 (1)
Osteoarthritis 2.5 1.9 (11) Cirrhosis 2.3 0.6 (25) Asthma 2.2 1.0 (17) Hypertensive heart
disease
1.9 1.9 (12)
COPD 2.3 2.7 (5) Lymphomas,
myelomas
1.5 0.4 (29) Schizophrenia 2.2 1.9 (13) Breast cancer 1.8 2.5 (8)
Colorectal cancer 2.0 1.3 (15) Liver cancer 1.5 0.2 (43) COPD 2.0 2.7 (5) Nephritis,
nephrosis
1.8 1.3 (16)
Migraine 1.6 0.8 (19) Lower respiratory
infections
1.5 5.7 (1) Cerebrovascular
disease
1.9 1.3 (14) Prostate cancer 1.6 0.4 (31)
Breast cancer 1.4 2.5 (8) Brain cancer 1.4 0.2 (44) Rheumatoid
arthritis
1.4 1.0 (18) Cirrhosis 1.3 0.6 (25)
Drug use
disorders
1.4 0.2 (41) HIV- AIDS 1.3 3.1 (4) Ischemic heart
disease
1.2 5.7 (2) Bladder cancer 1.3 0.2 (51)
Asthma 1.3 1.0 (17) Leukemia 1.3 0.8 (22) Panic disorder 1.2 0.2 (50) Liver cancer 1.3 0.2 (43)
Schizophrenia 1.3 1.9 (13) Bladder cancer 1.2 0.2 (51) Falls 1.0 0.2 (42) Lymphomas,
myelomas
1.2 0.4 (29)
Cirrhosis 1.2 0.6 (25) Nephritis,
nephrosis
1.1 1.3 (16) Parkinson disease 0.7 0.4 (30) Leukemia 0.9 0.8 (22)
Falls 0.9 0.2 (42) Prostate cancer 1.0 0.4 (31) Colorectal cancer 0.6 1.3 (15) Brain cancer 0.7 0.2 (44)
Rheumatoid
arthritis
0.8 1.0 (18) Hypertensive heart
disease
1.0 1.9 (12) Glaucoma 0.6 0.6 (26) Parkinson disease 0.7 0.4 (30)
HIV/AIDS 0.8 3.1 (4) Ovary cancer 0.8 0.2 (45) HIV- AIDS 0.5 3.1 (4) Kidney cancer 0.6 0.4 (32)
Panic disorder 0.7 0.2 (50) Falls 0.7 0.2 (42) Breast cancer 0.4 2.5 (8) Falls 0.5 0.2 (42)
*Data from 1983-2008. Disease subcategories are presented in decreasing order of burden of disease estimates in Spain 2006. DALY: Disability adjusted life years; YLL: Years of life lost; YLD: Years lived with disability;
COPD: Chronic Obstructive Pulmonary Disease; HIV- AIDS: Human Immunodeficiency Virus - Acquired Immunodeficiency Syndrome. Other disease subcategories covered by economic evaluation research (% of total
studies, [% of total DALYs]): Lower respiratory infections (5.7, [0.6]), Hepatitis B and C (3.3, [0.2]), Peptic ulcer (2.7, [0.1]), Childhood vaccinable diseases (2.1, [0.04]), Epilepsy (0.8, [0.3]), Multiple sclerosis (0.8, [0.2]),
Leukaemia (0.8, [0.6]), Cataracts (0.8, [0.1]), Laryngeal cancer (0.6, [0.3]), Benign prostatic hypertrophy (0.4, [0.2]), Melanoma (0.4, [0.2]), Cervical cancer (0.4, [0.2]), Appendicitis (0.4, [0.02]), Meningitis (0.4, [0.1]), Fires -
unintentional injuries (0.4, [0.1]), Tuberculosis (0.4, [0.1]), Pancreatitis (0.2, [0.2]), Rheumatic heart disease (0.2, [0.2]) and Otitis media (0.2, [0.06]).
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0evaluations (Table 2). In particular, depression and
dementias were in the first positions of DALYs rankings
for disease specific sub-categories, while in terms of eco-
nomic studies, they ranked 10 and 28, respectively
(Table 3). Similarly, sense organ diseases, respiratory
diseases, or some cardiovascular diseases (such as
stroke) and malignant neoplasms (lung and colorectal
cancers) are high in DALY rankings yet had a low num-
ber of economic evaluations conducted. In contrast,
infectious diseases, respiratory infections, diabetes or
digestive diseases are over-represented in terms of eco-
nomic reports as compared to their disease burden.
The Spearman’s correlation coefficients (r) between
economic evaluations and burden measures were calcu-
lated. By disease categories (n = 20), a moderate correla-
tion was seen between the various measures tested, the
highest being for total mortality (r = 0.671; p < 0.001),
followed by DALYs (r = 0.634; p = 0.003), YLLs (r =
0.540; p = 0.014) and YLDs (r = 0.508; p = 0.022). By
sub-categories (n = 51), weak, non-statistically signifi-
cant correlations were found (see data on Table 4). Data
log-transformation allowed for calculating the Pearson’s
correlation coefficients (r), finding a moderate associa-
tion by categories: 0.599 (p = 0.005) DALYs, 0.558 (p =
0.011) mortality, 0.473 (p = 0.035) YLLs and 0.399 (p =
0.091) YLDs. In the analysis of the main subcategories,
there was only a statistically significant correlation in
the case of DALYs, though it was still weak (r =0 . 2 7 7 ;
p = 0.049). For mortality, YLDs and YLLs, the correla-
tion coefficients were not statistically significant: 0.206
(p = 0.169), 0.197 (p = 0.165), and 0.165 (p = 0.272).
Figure 2 shows the actual and predicted values of the
economic evaluation studies using the number of
DALYs as predictive value in a linear regression model.
The distance from the points corresponding to the cate-
gories to their projection in the line means the differ-
ence between the existing economic evaluation studies
(observed values) and those that should be (expected
values) if they reflected burden of disease.
Discussion
The results of this analysis show that there is a mild to
moderate association between economic evaluations and
the burden of disease in the population. For some con-
ditions, a lower number of reports have been seen
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Figure 1 Relationship between burden of disease measures
and economic evaluation of healthcare interventions for the 3
broad disease groups of the Global Burden of Disease study.
Table 4 Spearman’s correlation coefficients (r) between burden of disease measures and diseases covered by
economic evaluations of healthcare interventions
Measure (year) Correlation coefficient (n = 20)* p-value Correlation coefficient (n = 51) p-value
Mortality (2006) 0.671 0.001 0.226 0.111
DALYs (2006) 0.634 0.003 0.267 0.058
YLLs (2006) 0.540 0.014 0.208 0.143
YLDs (2006) 0.508 0.022 0.226 0.111
* The results were statistically significant at a level 0.050 (bilateral).
DALYs: Disability adjusted life years; YLLs: Years of life lost; YLDs: Years lived with disability.
Units: Mortality (number of deaths per year), DALYs (years), YLLs (years) and YLDs (years).
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Figure 2 Relationship between disability adjusted life years
(DALYs) for 20 disease-categories and economic evaluation of
healthcare interventions. Note: The x and y axes are on
logarithmic scales. R
2 = 0.358; Adjusted R
2 = 0.323. The line
represents economic evaluation studies predicted on the basis of a
simple linear regression model with disability adjusted life years
(DALYs) as the explanatory variable.
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Page 6 of 10considering the burden they generate, as in the case of
accidents and injuries, some neuropsychiatric conditions,
sense organ diseases, cerebrovascular diseases, some
malignant neoplasms, or osteoarthritis. Furthermore, the
mismatching of economic evaluations compared to the
disease burden for infectious and parasitic diseases are
to be noted. An explanation to this could be the high
number of effective interventions available (e.g., antibio-
tics and vaccines) and that this has generated the need
to perform economic evaluations, amongst others
[18,19]. It could also be argued that the availability of
interventions with a known efficiency profile could have
generated some disinterest in performing new evalua-
tions, thus leading to a lower number of reports, as
could be the case for nutrition and physical activity
interventions to prevent adverse cardiovascular out-
comes. The lack of safety, efficacy and/or effectiveness
data on some interventions, particularly in diseases such
as Alzheimer’s dementia or drugs abuse, could have
decreased attention to the development of evaluations,
and even, in case they had been performed, could have
prevented disclosure of the findings given unfavorable
results [20]. For some of the health conditions (such as
accidents and injuries) where there have been a low
number of economic studies conducted there might be
a lesser number of researchers funded and/or interested
in costing trauma prevention and rehabilitation mea-
sures than other diseases.
It seems that particularly economic evaluation
research priorities are established by the interests and
concerns of the pharmaceutical industry and the investi-
gators or pressures from advocacy groups [21,22] which
could explain the prevalence of evaluations in interven-
tions to approach some diseases. With this regard, the
results of our study are consistent with those of other
previous studies that also evidenced disagreements
between the allocation of research resources and some
conditions with a substantial burden of disease
[5,7,9,10]. In the seminal U.S.-based study, Gross et al.
[5] examined the relationship between National Insti-
tutes of Health (NIH) funding and the burden of disease
for 29 conditions. They found that research funding was
more closely associated with DALYs than other burden
measures such as mortality, prevalence, incidence or
hospital days. Along the same line, Neumann et al. [10]
conducted the first study to look at economic evaluation
priorities. The authors found that cost-utility analyses
were generally associated with burden measures for 50
specific conditions. Comparing our correlation coeffi-
cients to those obtained in the U.S. and other Western
countries [10], the magnitude of the association between
DALYs and economic evaluation studies was extremely
poor: Spearman’s r =0 . 2 6 7( p=0 . 0 5 8 )v s .r =0 . 4 5 5( p
= 0.001). Our impression is that the health economics
research we have examined is not oriented towards
interventions to reduce the most burdensome diseases.
We believe these findings do not necessarily imply that
resources were allocated inefficiently, but rather raises
important questions to keep in mind when funding
future economic evaluations.
On the other hand, we further contextualized our
results within the National Health System. Figure 3
shows the overlapping of health priorities distinguishing
between: 1) Population health needs, influenced by
issues such as health determinants, current research and
development (R&D) agenda or the clinical practice in
health services, 2) NHS decision-makers evaluation
demand, that could be influenced by several scientific-
professional societies, political groups and/or the com-
munity and by the mass media, and, finally, 3) Public
resources relative to R&D in health, dependent on sev-
eral pressures (e.g., political, medical and/or social), his-
toric patterns, inertia or circumstancial problems when
the allocation procedure occurs (e.g., recently the health
crisis for pandemic influenza). In contrast, this research
has identified the lack of economic evaluations aimed at
public health interventions, diagnostic techniques, or
rehabilitation. The subject bias of the evaluations identi-
fied in the review towards therapeutic interventions
(generally medicines) would be due to the easier meth-
ods required for analysis. The efficacy of the treatments
has been extensively estimated under experimental con-
ditions, mainly through randomized clinical trials. Sec-
ond, the pharmaceutical industry has allocated a high
amount of resources to R&D with new products and
these have been marketed within the time window stu-
died, also simultaneously with the development and pro-
gressive addition of economic evaluation methods in the
National Healthcare System. Several papers have
demonstrated some form of cost-effectiveness is now
required for healthcare interventions to be covered by
many health administrations [23-25]. Then, it appears to
be normal that insurers intend to evaluate the economic
profitability of the new technologies and that private
companies are promoting the efficiency of their pro-
ducts to enhance market access, pricing and reimburse-
ment activities. The latter leads us to think about it
from a public health standpoint, as private profit-making
initiative investments do not necessarily intend to satisfy
community preferences (or its health needs), significant
health gains could be obtained from the resources avail-
able if health authorities prioritized the assessment of
efficiency, preferably of interventions that have been
extensively studied for a long time and that are aimed at
identifying health problems that affect large population
groups (or significant subpopulations) [26]. It is note-
worthy to mention the fact that complementary
approaches to prioritization exist in an effort to
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exclusively. In addition to the burden of disease and effi-
ciency approaches, criteria of social justice, social soli-
darity, and equity amongst special patient groups (e.g.,
rare diseases, children, elderly people) may be conci-
liated in determining health priorities [26,27]. In the
European Union, for exemple, the legislation for orphan
medicinal products (Regulation EC No 141/2000) and
for paediatrics (Regulation EC No 1901/2006) have suc-
cesfully included key elements to protect the interests of
these patient groups.
Some limitations can be highlighted in our study. First,
there is a lot of heterogeneity regarding the quality of the
economic evaluations identified in terms of the type of
intervention, targetted disease, methods, data sources,
and costs included. However, for the purpose of analysis
it has been considered that all studies included are
equally significant, which may not always be true.
Second, as in any review study, one could not rule out
the potential non-identification of some studies or dis-
agreements between the criteria of two reviewers. To
minimize this bias we used the largest search possible,
pre-defined inclusion criteria, and discussion of disagree-
ments between the investigators. Furthermore, publica-
tion bias may occur, as noted above. There may be an
even more important concern than bias, namely, screen-
ing a priori that may have been performed by the compa-
nies or producers of these analyses, which would make
that economic evaluations would have been only funded
in cases where a positive result was expected. These
biases could have been approached only increasing eco-
nomic evaluation funding from other sources, mainly
public ones [28]. Third, we recognize there exists some
arbitrary nature involved in clasifying economic evalua-
tion studies to specific disease subcategories and other
researchers may have classified them in a different way.
Figure 3 Health priorities overlapping through different perspectives in Spain. Note: Main disease categories (in boldface) and sub-
categories (in drawings). The information source for NHS R&D funding classification was derived from: Catalá-López et al. 2009. Other sources:
Burden of disease estimates (expressed as DALYs lost in 2006) proceeded from the present study. NHS priority-setting classification was
established by the following actions: 1) Statement of the Minister of Health and Social Policy to inform on the general policy lines of the
Department, at the Senate Commitee on Health. Madrid, June 18, 2009. Available from [in Spanish]: http://www.msc.es/gabinetePrensa/
discursosInterv/archivos/180609122907.pdf [accessed June 25, 2009]. 2) Quality Plan for the National Health System. Madrid: Ministry of Health
and Consumer Affairs, 2007. 3) Multisectorial Plan for HIV-AIDS: Spain 2008-2012. Madrid: Ministry of Health and Consumer Affairs, 2008. 4) Plan
for the Prevention and Control of Tuberculosis in Spain. Madrid: Ministry of Health and Consumer Affairs, 2008. 5) The NAOS Strategy: a Strategy
for Nutrition, Physical Activity, Obesity & Overweight Prevention. Madrid: Safety Food Agency - Ministry of Health and Consumer Affairs; 2005. 6)
The Spanish National Drugs Strategy 2009-2016. Ruling of 2 February 2009, of the Government Commission for the National Abuse Drug Plan,
publishing the Agreement of the Cabinet that approves the National Abuse Drug Strategy 2009-2016. Official State Journal (BOE) number 38 of
February 13th 2009.
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measures of population health have been proposed
including quality-adjusted life years (QALYs) or healthy
life years (HeaLY). The benefits and challenges of these
measures have been examined [29,30]. As the DALYs has
been the most widely-used measure in priority setting for
global health, we focused on it in this study. Some of the
limitations of the DALY approach refer to the parameters
used for the their calculation, such as social preferences
to establish the disability weights, discounting and age
weighting. Furthermore, the methodology we used did
not allowed to include co-morbities in the DALYs calcu-
lation, despite its importance in terms of quality of life,
healthcare ressource use, costs and mortality [31-33].
D e s p i t et h i sf a c t ,w et h i n kt h a tD A L Y sa r eam e a s u r eo f
the most relevant health outcomes than theoretically
more objective measures, such as deaths averted or life
years gained (not adjusted). In future investigations, it
would be interesting to perform an approach in line with
the Australian burden of disease study [34], where for the
first time DALYs were calculated considering co-morbid-
ity of non-fatal conditions in the elderly age, some mental
disorders, congenital anomalies and accidents, and the
burden attributable to the main risk factors.
Conclusions
The current need for measuring health losses in the
population is unquestionable considering both the fatal
and the disabling consequences of diseases to obtain a
more complete information on the health problems.
With this regard, estimating DALYs means an approach
in the identification of immediate needs. Examining dis-
crepancies between the numbers of economic evaluations
in particular diseases and the overall burden of disease
helps shed light on whether there are potentially over-
and under-investigated areas. In terms of economic eva-
luative studies, this analysis shows that some research
areas require greater attention by researchers and policy
makers, specifically neuropsychiatric conditions, acci-
dents and injuries, sense organ diseases, respiratory dis-
eases, or some cardiovascular diseases (such as stroke)
and malignant neoplasms (lung and colorectal cancers).
Regulatory authorities, HTA agencies, universities or
other public-private organizations could lead the change,
dedicating more research lines to prevention, diagnosis
and rehabilitation, diversifying interventions to condi-
tions generating in the population a significant burden
without neglecting other socially priority conditions (as
in the case of rare diseases or paediatric populations).
Establishing health priorities is a complex process where
multiple circumstances interfere (e.g. such as political deci-
sions, the economic situation, etc.). Despite being one of
the key points in the development of any health policy,
many times making decisions about the health problems to
be prioritized is accomplished unclearly and for reasons not
always reasoned adequately. With this regard, the reduction
of the burden of disease is an explicit criterion that, in com-
bination with others such as efficiency (cost-effectiveness)
and social equity, can allow for issuing recommendations to
guide the debates about setting research priorities and,
therefore, improving population health.
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